| miR-338 acts as a novel tumor suppressor gene in gastric cancervby targeting NRP1 expression | gastric, |
| These findings revealed that miR3383p may act as a tumor suppressor that blocks the growth of human ovarian epithelial carcinoma through PI3K/AKT signaling pathways by targeting Runx2. | ovarian, |
| These findings revealed that miR338-3p may act as a tumor suppressor in breast cancer by targeting SOX4 | breast, |
| microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients | prostate, |
| lncRNA-Snhg1 promoted cell proliferation by acting as a non-degradable sponge for the tumor suppressor miR-338 in esophageal cancer cells. | esophageal, |
| These data identify miR-338-3p as a clinically relevant tumor suppressor in glioblastoma. | glioblastoma, |
| Findings indicate that miR-338-3p acts as a tumor suppressor in gastric cancer (GC) and tissue miR-338-3p might serve as a prognostic biomarker of GC. | gastric, |
| miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B | gastric, |
| The tumor suppressor role of microRNA-338-3p in renal cell carcinoma | kidney, |
| MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1 | glioma, |
| miR-338-5p expression is lower in esophageal squamous cell carcinoma (ESCC) cells compared with normal cells. miR-338-5p reduced cell proliferation, colony formation, migration and cisplatin resistance in an ESCC cell line, CE-81T. Luciferase assays showed the direct binding between miR-338-5p and the 3_ untranslated region of FERMT2 suggesting that miR-338-5p may play an antioncogenic role in ESCC via repressing FERMT2. | colorectal,esophageal, |
| Inhibition of hsa_circ_0001313 (circCCDC66) induction enhances the radio-sensitivity of colon cancer cells via tumor suppressor miR-338-3p: Effects of cicr_0001313 on colon cancer radio-sensitivity | colorectal, |
| the present study is the first to demonstrate that miR-338-3p functions as a tumor suppressor in multiple myeloma (MM)through inhibiting CDK4. This finding implies that miR-338-3p is a potential therapeutic target for the treatment of MM. | None |